Haplo-cord HCT vs. Haplo-HCT for T-ALL Patients

Haploidentical Hematopoietic Stem Cell Transplantation Clinical Trial

Official title: Haploidentical Hematopoietic Cell Transplantation Combined With an Unrelated Cord Blood Unit for Acute T Cell Lymphoblastic Leukemia Compared to Haploidentical Hematopoietic Cell Transplantation: a Multicenter, Randomized, Open-label Trial

Status Recruiting

Clinical Trial Summary

The goal of this clinical trial is to learn if haploidentical hematopoietic cell transplantation combined with an unrelated cord blood unit (haplo-cord HCT) works to treat acute T cell lymphoblastic leukemia (T-ALL). It will also learn about the safety of the transplantation. The main questions it aims to answer are:

Dose co-infusion of cord blood in haploidentical hematopoietic cell transplantation (haplo-HCT) lower the rate of relapse? What medical problems do participants have when having haplo-cord HCT? Researchers will compare haplo-cord HCT to haplo-HCT to see if haplo-cord HCT works to treat T-ALL.

Participants will be infused an unrelated cord blood unit at the same day of haploidentical graft infusion.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Cord Blood
• Haploidentical Hematopoietic Stem Cell Transplantation
• Leukemia
• Leukemia, Lymphoid
• Precursor Cell Lymphoblastic Leukemia-Lymphoma
• Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

• NCT number: NCT06381817
• Study type: Interventional
• Source: The First Affiliated Hospital of Soochow University
• Contact: Yang XU
• Phone: 86+051267781850
• Email: xuyang1020@126.com
• Status: Recruiting
• Phase: Phase 3
• Start date: April 1, 2024
• Completion date: March 31, 2028